Table 3.

Basic rules and timing of vaccination against COVID-19 in transplant recipients and candidates—summary based on references [30,31,32,33,34,35]. Abbreviations: aHUS, atypical haemolytic uremic syndrome; AR, acute rejection; ASTS, American Society of Transplant Surgeons; IS, immunosuppression; Tx, transplant.

(1)	Candidates for solid organ transplantation on a waiting list should be vaccinated before transplantation
(2)	Patients after Tx should be vaccinated if there are no strong contraindications
(3)	COVID-19 vaccination of patients early after Tx with standard IS regiment should be deferred for +/− 3–6 months after Tx (1 month in Poltransplant recommendation)
(4)	COVID-19 vaccination of patients early after Tx with IS regiment consisting of T cell ablative therapy should be deferred for +/− 3–6 months after Tx
(5)	After treatment of AR, vaccination should be deferred +/− 1 month
(6)	COVID-19 vaccination of patients after Tx who underwent B cell ablative therapy (RTX) should be deferred for +/− 3–6 months and B cell screen should be performed (count of B cells in peripheral blood sample)
(7)	mRNA vaccines are considered not to increase the risk of AR; however, there is lack of evidence of immunoresponsiveness for vaccination in patients after Tx
(8)	Patients with aHUS and kidney transplant on eculizumab should be vaccinated against COVID-19
(9)	There is lack of recommendations for vector based vaccines; however, the ASTS underlines that up to now, they have not recommended live viral vector vaccines for transplant patients